Literature DB >> 3793326

Clofazimine-mediated regulation of human polymorphonuclear leukocyte migration by pro-oxidative inactivation of both leukoattractants and cellular migratory responsiveness.

R Anderson, P Lukey, C Van Rensburg, U Dippenaar.   

Abstract

The effects of clofazimine (0.15-20 micrograms/ml) on the spontaneous and N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP)-stimulated migration, membrane-associated oxidative metabolism, degranulation and production of prostaglandin (PG) E2 by human polymorphonuclear in vitro have been investigated. Clofazimine at concentrations of 0.3 microgram/ml and greater significantly increased both the spontaneous and FMLP-stimulated chemiluminescence (CL), hexose monophosphate shunt (HMS) activity, myeloperoxidase-mediated protein iodination, auto-iodination, degranulation and PGE2 production by PMNL. At the same concentrations clofazimine inhibited both random and leukoattractant-induced migration of PMNL. Inhibition of PMNL migration by clofazimine was due to both a cell-directed auto-oxidative mechanism and by functional inactivation of FMLP. Clofazimine mediated inhibition of PMNL migration was prevented by the anti-oxidants cysteine and dapsone but not by the potent inhibitors of PG synthetase indomethacin and piroxicam. Anti-oxidants also protected FMLP from functional inactivation by clofazimine-exposed PMNL. Clofazimine increased both the spontaneous and FMLP-stimulated production of PGE2 by PMNL from four children with chronic granulomatous disease (CGD). Clofazimine is not an oxidising agent nor did it stimulate membrane-associated oxidative metabolism in CGD or NaF-pulsed normal PMNL. These data show that clofazimine-mediated inhibition of PMNL migration is dependent on intact cellular membrane-associated oxidative metabolism. Clofazimine is therefore a pro-oxidative anti-inflammatory agent.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3793326     DOI: 10.1016/0192-0561(86)90033-0

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  5 in total

1.  HLA expression in hepatocellular carcinoma cell lines.

Authors:  A A Wadee; A Paterson; K A Coplan; S G Reddy
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

2.  Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas.

Authors:  Scott M Irwin; Veronica Gruppo; Elizabeth Brooks; Janet Gilliland; Michael Scherman; Matthew J Reichlen; Rachel Leistikow; Igor Kramnik; Eric L Nuermberger; Martin I Voskuil; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

3.  Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo.

Authors:  N H Afdhal; A Long; J Lennon; J Crowe; D P O'Donoghue
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

4.  The inhibitory effects of Mycobacterium tuberculosis on MHC class II expression by monocytes activated with riminophenazines and phagocyte stimulants.

Authors:  A A Wadee; R H Kuschke; T G Dooms
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

Review 5.  Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy.

Authors:  Verena Hofschröer; Karolina Najder; Micol Rugi; Rayhana Bouazzi; Marco Cozzolino; Annarosa Arcangeli; Gyorgy Panyi; Albrecht Schwab
Journal:  Front Pharmacol       Date:  2021-01-19       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.